Selected HMG-CoA Reductase Inhibitors/Telithromycin
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Telithromycin may slow down how quickly your liver processes your cholesterol medicine.
What might happen:
The blood levels of your cholesterol medicine may increase and cause toxic effects.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together. You may need to take a different cholesterol medicine or stop taking your cholesterol medicine while you are taking your antibiotic.Tell your doctor right away if you experience muscle pain, tenderness, or weakness; unexplained tiredness; or discolored urine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Ketek (telithromycin) UK summary of product characteristics. Sanofi-Aventis June 2, 2009.
2.Ketek (telithromycin) US prescribing information. Sanofi-Aventis U.S. LLC December, 2010.
3.Mevacor (lovastatin) US prescribing information. Merck & Co., Inc. February, 2012.
4.USFood and Drug Administration. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. available at: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm June 8, 2011.
5.Zocor (simvastatin) US prescribing information. Merck & Co., Inc. October, 2013.
6.Vytorin (ezetimibe/simvastatin) US prescribing information. Merck/Schering-Plough Pharmaceuticals October, 2012.
7.Baycol (cerivastatin) US prescribing information. Bayer Corporation December, 2000.
8.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.